About Biosion
Biosion is a company based in Nanjing (China) founded in 2017 by Mingjiu Chen. Biosion has raised $76.44 million across 4 funding rounds from investors including HMC Ventures, GF Xinde Investment Management and Fangyi Equity Investment Fund. Biosion operates in a competitive market with competitors including Actelion, Sana Biotechnology, Janux Therapeutics, GigaGen and ASLAN Pharmaceuticals, among others.
- Headquarter Nanjing, China
- Founders Mingjiu Chen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$76.44 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
HMC Ventures
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Biosion
Unlock access to complete
Unlock access to complete
Funding Insights of Biosion
Biosion has successfully raised a total of $76.44M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biosion
Biosion has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include HMC Ventures, GF Xinde Investment Management and Fangyi Equity Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Biosion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosion
Investment portfolio details for Biosion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biosion
Detailed financials for Biosion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosion Comparisons
Peer comparison for Biosion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biosion
Biosion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Sana Biotechnology, Janux Therapeutics, GigaGen and ASLAN Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Targeted small molecules are developed for oncology treatments.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Biosion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosion
Complete news archive for Biosion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosion
Biosion was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Biosion is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Mingjiu Chen is the current CEO of Biosion. They have also founded this company.
Biosion is a funded company, having raised a total of $76.44M across 4 funding rounds to date.
Biosion was founded in 2017 and is headquartered in Nanjing, China. Antibody-based therapeutics are developed by the company to address diseases such as asthma, atopic dermatitis, chronic obstructive pulmonary disease, solid cancers, and blood cancers. Drug candidates including BSI 045A, which targets IL4R, and BSI 045B for respiratory conditions are advanced. Additionally, BSI 038 is targeted at CD40 for oncology applications. Operations focus on immunotherapy innovations in the biotechnology sector.
Biosion's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
Biosion has 9 investors. Key investors include HMC Ventures, GF Xinde Investment Management, Fangyi Equity Investment Fund, Addor Capital, and Suxin Venture Capital.